Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL4467551 | 0.88 | RAB9A (0.44) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL4467542 | 0.88 | RAB9A (0.44) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL4097428 | 0.85 | RAB9A (0.44) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL17560577 | 0.84 | FADS1 (0.39) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL10310181 | 0.82 | MEN1 (0.62) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL12889264 | 0.82 | PLAU (0.40) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL4795850 | 0.79 | ALDH1A1 (0.61) | RAB9ANPC1ALDH1A1HPGDTSHR | |
| SCHEMBL1933289 | 0.79 | KMT2A (0.50) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL8741155 | 0.78 | TSHR (0.43) | RAB9ANPC1MEN1KMT2AHPGD | |
| SCHEMBL10310245 | 0.78 | CYP1A2 (0.46) | RAB9ANPC1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-0961618-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6369068-B1 | Amino substituted pyrimidine containing compounds | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| EP-0961618-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5869660-A | Process of preparing imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998025619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5739143-A | Imidazole compounds and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | RAB9A 2488/4885NPC1 3558/4885MEN1 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.